Morphosys, Daiichi Sankyo to Develop Therapeutic Antibodies Against Hospital-Acquired Infections

Oct 23, 2009

Premium

This story originally ran on Oct. 21.

German antibody firm Morphosys announced this week a collaboration with Japanese pharma Daiichi Sankyo for the development of therapeutic antibodies against hospital-acquired infections.

Daiichi Sankyo becomes Morphosys's first collaborator using Morphosys' HuCAL Platinum antibody library for new drug discovery in infectious diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three for Immunotherapy

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

Cancer-Fighting Zombies

Elephants may have "re-animated" pseudogenes to help stave off cancer, according to the New York Times.

This Week in Genome Research

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.